EMA Authorised: Zadenvi (denosumab) — Zentiva k.s.

View source ↗

Summary

EMA authorised Zadenvi (denosumab) for osteoporosis, including postmenopausal osteoporosis, with Zentiva k.s. as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Zadenvi (denosumab)

Snippet

Status: Authorised. Therapeutic area: Bone Resorption;Osteoporosis;Osteoporosis, Postmenopausal. MAH: Zentiva k.s.. Decision date: 03/10/2025